Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph K Eibl

Showing results (1-10 of 55) with videos related to

Pageof 6
Sort By:
Canadian Journal of Physiology and Pharmacology|April 16, 2010
Zinc-metallothionein: a potential mediator of antioxidant defence mechanisms in response to dopamine-induced stressJoseph K Eibl, Zouleika Abdallah, Gregory M Ross
Drug and Alcohol Dependence|August 1, 2018
Improved treatment-retention for patients receiving methadone dosing within the clinic providing physician and other health services (onsite) versus dosing at community (offsite) pharmaciesGraham Gauthier, Joseph K Eibl, David C Marsh
Neurochemistry International|October 30, 2012
Structural, biological, and pharmacological strategies for the inhibition of nerve growth factorJoseph K Eibl, Bridget C Strasser, Gregory M Ross
European Journal of Pharmacology|March 27, 2013
Identification of novel pyrazoloquinazolinecarboxilate analogues to inhibit nerve growth factor in vitroJoseph K Eibl, Bridget C Strasser, Gregory M Ross
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|May 20, 2017
The State of Opioid Agonist Therapy in Canada 20 Years after Federal OversightJoseph K Eibl, Kristen Morin, Esa Leinonen, et al.
Substance Abuse Treatment, Prevention, and Policy|September 21, 2016
Too much or never enough: a response to Treatment of opioid disorders in Canada: looking at the 'other epidemic'Joseph K Eibl, Kristen A Morin-Taus, David C Marsh
The International Journal on Drug Policy|January 1, 2021
Evidence of increased Fentanyl use during the COVID-19 pandemic among opioid agonist treatment patients in Ontario, CanadaKristen A Morin, Shreedhar Acharya, Joseph K Eibl, et al.
European Addiction Research|March 11, 2021
A Retrospective Cohort Study Comparing In-Person and Telemedicine-Based Opioid Agonist Treatment in Ontario, Canada, Using Administrative Health DataKristen A Morin, Matthiew D Parrotta, Joseph K Eibl, et al.
Plos One|November 9, 2017
The impact of cannabis use on patients enrolled in opioid agonist therapy in Ontario, CanadaAlexandra M Franklyn, Joseph K Eibl, Graham J Gauthier, et al.
Substance Abuse Treatment, Prevention, and Policy|November 4, 2017
The opioid crisis: past, present and future policy climate in Ontario, CanadaKristen A Morin, Joseph K Eibl, Alexandra M Franklyn, et al.
Pageof 6

Showing results (1-10 of 55) with videos related to

Sort By:
Pageof 6
Canadian Journal of Physiology and Pharmacology|April 16, 2010
Zinc-metallothionein: a potential mediator of antioxidant defence mechanisms in response to dopamine-induced stressJoseph K Eibl, Zouleika Abdallah, Gregory M Ross
Drug and Alcohol Dependence|August 1, 2018
Improved treatment-retention for patients receiving methadone dosing within the clinic providing physician and other health services (onsite) versus dosing at community (offsite) pharmaciesGraham Gauthier, Joseph K Eibl, David C Marsh
Neurochemistry International|October 30, 2012
Structural, biological, and pharmacological strategies for the inhibition of nerve growth factorJoseph K Eibl, Bridget C Strasser, Gregory M Ross
European Journal of Pharmacology|March 27, 2013
Identification of novel pyrazoloquinazolinecarboxilate analogues to inhibit nerve growth factor in vitroJoseph K Eibl, Bridget C Strasser, Gregory M Ross
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|May 20, 2017
The State of Opioid Agonist Therapy in Canada 20 Years after Federal OversightJoseph K Eibl, Kristen Morin, Esa Leinonen, et al.
Substance Abuse Treatment, Prevention, and Policy|September 21, 2016
Too much or never enough: a response to Treatment of opioid disorders in Canada: looking at the 'other epidemic'Joseph K Eibl, Kristen A Morin-Taus, David C Marsh
The International Journal on Drug Policy|January 1, 2021
Evidence of increased Fentanyl use during the COVID-19 pandemic among opioid agonist treatment patients in Ontario, CanadaKristen A Morin, Shreedhar Acharya, Joseph K Eibl, et al.
European Addiction Research|March 11, 2021
A Retrospective Cohort Study Comparing In-Person and Telemedicine-Based Opioid Agonist Treatment in Ontario, Canada, Using Administrative Health DataKristen A Morin, Matthiew D Parrotta, Joseph K Eibl, et al.
Plos One|November 9, 2017
The impact of cannabis use on patients enrolled in opioid agonist therapy in Ontario, CanadaAlexandra M Franklyn, Joseph K Eibl, Graham J Gauthier, et al.
Substance Abuse Treatment, Prevention, and Policy|November 4, 2017
The opioid crisis: past, present and future policy climate in Ontario, CanadaKristen A Morin, Joseph K Eibl, Alexandra M Franklyn, et al.
Pageof 6